RESEARCH COLLABORATION TERMINATION AGREEMENTCollaboration Termination Agreement • November 9th, 2009 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations
This Research Collaboration Termination Agreement (this “Termination Agreement”), effective as of June 22, 2009 (the “Effective Date”), is made by and between N. V. Organon, a company organized under the laws of The Netherlands, having a principal place of business at Kloosterstraat 6, 5342 AB Oss, The Netherlands (hereinafter referred to as “Organon”); and Ligand Pharmaceuticals Incorporated, a Delaware corporation, having a principal place of business at 10275 Science Center Drive, San Diego, California 92121 (hereinafter referred to as “Ligand”).
COLLABORATION TERMINATION AGREEMENTCollaboration Termination Agreement • June 9th, 2009 • Wex Pharmaceuticals Inc. • In vitro & in vivo diagnostic substances
COLLABORATION TERMINATION AGREEMENTCollaboration Termination Agreement • September 2nd, 2011 • Argos Therapeutics Inc • Pharmaceutical preparations • New York
This Collaboration Termination Agreement (“Agreement”) dated the 31st day of December, 2009 (the “Termination Date”) is by and between Argos Therapeutics, Inc. (formerly known as Merix Bioscience, Inc.), a corporation organized and existing under the laws of the State of Delaware and having its principal office at 4233 Technology Drive, Durham, North Carolina 27704 (“Argos”), and Kyowa Hakko Kirin Co., Ltd. (formerly known as Kirin Brewery Company, Limited), a Japanese corporation having its principal office at 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo, 100-8185 Japan (“KHK”).
VOLUNTARY ANNOUNCEMENT - COLLABORATION TERMINATION AGREEMENTCollaboration Termination Agreement • December 30th, 2019
This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the “Company”, together with its subsidiaries, the “Group”) on a voluntary basis. Please also refer to the overseas regulatory announcement published by the Company on 30 December 2019.
